作者
Soumen Khatua, Anne Song, Divyaswathi C Sridhar, Stephen C Mack
发表日期
2018/8/1
来源
Current neuropharmacology
卷号
16
期号
7
页码范围
1045-1058
出版商
Bentham Science Publishers
简介
Background
Medulloblastoma is the most common malignant brain tumor in children, currently treated uniformly based on histopathology and clinico-radiological risk stratification leading to unpredictable relapses and therapeutic failures. Identification of molecular subgroups have thrown light on the reasons for these and now reveals clues to profile molecularly based personalized therapy against these tumors.
Methods
Research and online contents were evaluated for pediatric medulloblastoma which included latest information on the molecular subgroups and their clinical relevance and update on efforts to translate them into clinics.
Results
Scientific endeavors over the last decade have clearly identified four molecular variants (WNT, SHH, Group 3, and Group 4) and their demographic, genomic, and epigenetic profile. Latest revelations include significant heterogeneity within these subgroups and 12 different …
学术搜索中的文章
S Khatua, A Song, DC Sridhar, SC Mack - Current neuropharmacology, 2018